CompletedEarly Phase 1ACTRN12610000114044

A randomized double blind, placebo-controlled clinical trial with oral n-acetylcysteine in systemic sclerosis patients and assessment of skin blood flow of the hands with laser Doppler perfusion imaging

Oral N-acetylcysteine in the Treatment of Raynaud's Phenomenon Secondary to Systemic Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial

Sponsor

Foundation for the support for research in the state of Sao Paulo

Enrollment

40 participants

Start Date

Aug 25, 2008

Study Type

Interventional

Conditions

microcirculation fingertip blood flow

Summary

analyze the effect of oral N-acetylcysteine on microcirculation by laser Doppler perfusion imaging in systemic sclerosis patients

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 65 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests whether a supplement called N-acetylcysteine can improve blood flow and reduce pain in people with Raynaud's phenomenon caused by systemic sclerosis. Adults aged 18 to 65 who are non-smokers and do not have diabetes may participate.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

participants will receive capsules with n-acetylcysteine 600 mg three applications per day orally for 4 weeks to be provided by a developer who did not attend the previous steps

Locations(1)

Sao Paulo, Brazil

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12610000114044